Granules India

GRANULES.NS

Hyderabad, India· Est. 1991

granulesindia.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

GRANULES.NS · Stock Price

INR 743.50+302.60 (+68.63%)

Market Cap: $2.0B

Historical price data

Market Cap: $2.0BPatents: 3Founded: 1991Employees: 6500+HQ: Hyderabad, India

Sector Ranking#36 in Small Molecule Drugs

Overview

Granules India is a mission-driven pharmaceutical company focused on manufacturing high-quality, affordable essential medicines through a vertically integrated model. Its strategic achievements include establishing a global footprint with 10 manufacturing facilities, securing over 69 ANDA approvals, and serving 300+ customers in 80+ countries. The company's growth strategy is anchored in operational excellence, process innovation, and expanding its portfolio in complex generics and controlled substances to drive sustainable, profitable expansion.

Analgesics/Anti-inflammatoryAnti-infectivesCardiovascularCNSDiabetesAntihistamines

Technology Platform

A vertically integrated manufacturing platform combining advanced chemical synthesis, formulation science, and process optimization for the production of generic APIs, intermediates, and finished dosages.

Funding History

IPOUndisclosedUndisclosedJun 15, 2005

FDA Approved Drugs

METOPROLOL SUCCINATEANDAAug 7, 2023

LOSARTAN POTASSIUMANDAFeb 23, 2023

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONEANDAAug 29, 2022

Opportunities

Granules is poised to capitalize on global supply chain diversification away from China ('China+1'), the growing demand for chronic disease medications, and the higher-margin complex generics and controlled substances market.

Its integrated model provides a unique competitive advantage in securing partnerships with global pharma companies.

Risk Factors

Key risks include intense pricing pressure in commodity generics, regulatory compliance challenges across multiple geographies, volatility in raw material costs and supply, and execution risks associated with scaling up its complex generics portfolio.

Competitive Landscape

Granules competes with large Indian integrated pharma companies (e.g., Dr. Reddy's, Sun Pharma) and Chinese API manufacturers. Its differentiation stems from full vertical integration, scale in key molecules, a strong regulatory track record, and a strategic shift towards higher-value complex generics and formulations.